TMBR / Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million. more_horizontal

Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is undergoing a massive rally on Monday after announcing that Leo US is acquiring it in a $36 million de more_horizontal

Timber (TMBR) receives a dermal carcinogenicity waiver from the FDA for TMB-001, which is being developed to treat moderate-to-severe subtypes of cong more_horizontal

Timber Pharmaceuticals, Inc. (TMBR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In more_horizontal

Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is taking off on Friday after getting an orphan drug designation in Europe. That comes from the EC and more_horizontal

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America more_horizontal

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America more_horizontal

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America more_horizontal